{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-052058","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2024-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.018489+00:00","generated_at":"2026-06-03T00:11:42.040139+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"aTyr Pharma Q1 2024 update: Phase 3 EFZO-FIT completes enrollment expected in Q2 2024","bullets":["Cash, cash equivalents, restricted cash and investments totaled $87.7 million as of March 31, 2024.","Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis enrollment completion expected in Q2 2024.","Phase 2 EFZO-CONNECT study in systemic sclerosis-associated ILD enrolling at multiple U.S. sites.","R&D expenses of $13.4 million and G&A expenses of $3.5 million for Q1 2024.","Collaboration revenue of $0.2 million from Kyorin agreement for drug product material sold."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-052058","json":"https://secwatch.observer/filing/0000950170-24-052058.json","markdown":"https://secwatch.observer/filing/0000950170-24-052058.md","text":"https://secwatch.observer/filing/0000950170-24-052058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024052058/0000950170-24-052058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024052058/life-20240502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T00:11:42.040139+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"97d607043bb977c98481ce8a61d8ddd66aebf14e","claim":"aTYR PHARMA INC reported financial results for the three months ended March 31, 2024.","evidence_excerpt":"On May 2, 2024, aTyr Pharma, Inc. issued a press release announcing financial results for the three months ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024052058/0000950170-24-052058-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}